An integrative biology approach for analysis of drug action in models of human vascular inflammation
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Unexpected drug activities discovered during clinical testing establish the need for better characterization of compounds in human disease‐relevant conditions early in the discovery process. Here, we describe an approach to characterize drug function based on statistical analysis of protein expression datasets from multiple primary human cell‐based models of inflammatory disease. This approach, termed Biologically Multiplexed Activity Profiling (BioMAP), provides rapid characterization of drug function, including mechanism of action, secondary or off‐target activities, and insights into clinical phenomena. Using three model systems containing primary human endothelial cells and peripheral blood mononuclear cells in different environments relevant to vascular inflammation and immune activation, we show that BioMAP profiles detect and discriminate multiple functional drug classes, including glucocorticoids; TNF‐α antagonists; and inhibitors of HMG‐CoA reductase, calcineurin, IMPDH, PDE4, PI‐3 kinase, hsp90, and p38 MAPK, among others. The ability of cholesterol lowering HMG‐CoA reductase inhibitors (statins) to improve outcomes in rheumatic disease patients correlates with the activities of these compounds in our BioMAP assays. In addition, the activity profiles identified for the immunosuppressants mycophenolic acid, cyclosporin A, and FK‐506 provide a potential explanation for a reduced incidence of posttransplant cardiovascular disease in patients receiving mycophenolic acid. BioMAP profiling can allow integration of meaningful human biology into drug development programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated Genomic and Proteomic Analyses of a Systematically Perturbed Metabolic Network
Ideker, T., Thorsson, V., Ranish, J. A., Christmas, R., Buhler, J., Eng, J. K., Bumgarner, R., Goodlett, D. R., Aebersold, R., & Hood, L. (2001) · Science · doi:10.1126/science.292.5518.929 · Cited by 2,050
A vision for the future of genomics research
Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S., & on behalf of the US National Human Genome Research Institute (2003) · Nature · doi:10.1038/nature01626 · Cited by 1,752
A novel anti-inflammatory role for simvastatin in inflammatory arthritis.
Leung, B. P., Sattar, N., Crilly, A., Prach, M., McCarey, D. W., Payne, H., Madhok, R., Campbell, C., Gracie, J. A., Liew, F. Y., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1524 · Cited by 434
Cited by
Systems biology in drug discovery
Butcher, E. C., Berg, E. L., & Kunkel, E. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1017 · Cited by 605
Self-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
The evasive nature of drug efficacy: implications for drug discovery
Galandrin, S., Oligny-Longpré, G., & Bouvier, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.005 · Cited by 363
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism
Kenakin, T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1875 · Cited by 317
Metadata
- Authors
- Kunkel, E. J., Dea, M., Ebens, A., Hytopoulos, E., Melrose, J., Nguyen, D., Ota, K. S., Plavec, I., Wang, Y., Watson, S. R., Butcher, E. C., & Berg, E. L.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2004-06-18
- Volume
- 18
- Issue
- 11
- Pages
- 1279-1281
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2142333178
- Cited by
- 83
- References
- 3
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An integrative biology approach for analysis of drug action in models of human vascular inflammation. https://app.cochat.ai/papers/10.1096/fj.04-1538fje
- The paper
- Kunkel, E. J., Dea, M., Ebens, A., Hytopoulos, E., Melrose, J., Nguyen, D., Ota, K. S., Plavec, I., Wang, Y., Watson, S. R., Butcher, E. C., & Berg, E. L. (2004). An integrative biology approach for analysis of drug action in models of human vascular inflammation. The FASEB Journal. https://doi.org/10.1096/fj.04-1538fje
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.